Eli Lilly is expanding the Indianapolis-based company’s footprint in Indiana through a $2.1 billion investment.
Several U.S. states on March 25 announced broad expansions of their Covid-19 vaccine rollouts, with California opening immunizations to all adults aged 50 and older starting April 1 and Florida making anyone 40 and up eligible from March 22.
A large plant being used to manufacture Johnson & Johnson’s Covid-19 vaccine was cleared by U.S. regulators on March 23, setting the stage for the weekly U.S. supply to surge more than 20 percent.
Walmart Inc. is preparing to offer Covid-19 vaccinations in seven more states, as well as in Chicago and Puerto Rico, expanding beyond the two states where the company’s pharmacists are offering inoculations.
U.S. coronavirus infections surged by at least 129,606, according to a Reuters tally, the third consecutive daily rise of more than 100,000 cases as a third wave of Covid-19 sweeps the United States.
The United States set a one-day record for new coronavirus cases with at least 102,591 new infections and as hospitals in several states reported a rising tide of patients, according to a Reuters tally.
Point-of-care testing is a critical tool in the battle against Covid-19, and researchers in Indiana are working around the clock to deliver rapid tests with high specificity.
Amidst the pandemic, the biopharma industry continues to surge ahead as BioSpace reviews companies that have made recent job announcement expansions.
As the number of diagnosed cases of COVID-19 continues to rise in the United States, Eli Lilly partnered with the Indiana State Department of Health to accelerate testing for the virus in that state.
While employees of Cambridge, Massachusetts-based Biogen who attended a management meeting in Boston tested positive for COVID-19, numerous biopharma organizations are cancelling or postponing activities that involve large groups of people.
